8-K: Solsence Q3 Revenue Drops, Leadership Shifts Amid Strategic Overhaul

Solsence, Inc. reported a 14% revenue decrease and a net loss in Q3 2025, alongside significant executive leadership changes and operational restructuring aimed at driving future growth and profitability.

Summary

• Revenue for the third quarter of 2025 was $14.5 million, a 14% decrease compared to $16.9 million for the same period in 2024.
• Gross margin in Q3 2025 was 23%, down from 36% in Q3 2024, resulting in a gross profit of $3.4 million compared to $6.1 million in Q3 2024.
• A net loss of $1.1 million was reported for Q3 2025, contrasting with a net income of $3.0 million in Q3 2024.
• Adjusted EBITDA for the quarter was a loss of $435,000, compared to a positive $3.6 million in Q3 2024.
• Operating expenses increased to $4.2 million in Q3 2025 from $2.9 million in Q3 2024, driven by higher employee-related costs, legal fees, allowance for credit loss, severance costs, and Nasdaq uplisting expenses.
• Kevin Cureton was promoted to President and Chief Executive Officer, Laura Riffner was appointed Chief Financial Officer, and Yoana Dvorzsak was named Vice President, Innovation and Product Integrity.
• Operational improvements include unifying R&D and Quality teams, consolidating manufacturing facilities from three to two, and enhancing automation to streamline processes.
• These operational changes led to a nearly 25% reduction in average labor cost per unit year-over-year and a 10 percentage point increase in Overall Equipment Effectiveness (OEE) performance.
• The company expects a mid-six-figure reduction in annual operating costs from facility consolidation and a high six-figure to low seven-figure reduction in direct labor expense annually from efficiency savings.
• For the nine months ended September 30, 2025, net revenue was $49.581 million, up from $39.780 million in the prior year, with net income of $1.627 million compared to $4.793 million.
• An Employee Retention Credit (ERC) payment of $1.2 million and $300,000 in related interest were received in Q2 2025, positively impacting the nine-month results.

Sentiment

Score: 4

Explanation: While Q3 2025 financial results were significantly worse year-over-year, the company is undergoing a strategic transformation with new leadership and operational improvements that are expected to yield positive results in the future. The full-year revenue projection remains positive, and the company operates in a growing market segment. However, the immediate financial performance is a concern.

Positives

• Strategic transformation with key executive leadership changes, including the promotion of Kevin Cureton to President and CEO, appointment of Laura Riffner as CFO, and Yoana Dvorzsak to lead Innovation and Product Integrity.
• Unified R&D and Quality teams under one leader to improve product design, clarity of requirements, and control, aiming for products to be 'made right the first time'.
• Consolidated manufacturing facilities from three to two, projected to yield a mid-six-figure reduction in annual operating costs.
• Improved automation and Overall Equipment Effectiveness (OEE) performance by 10 percentage points, leading to a nearly 25% reduction in average labor cost per unit year-over-year.
• Expected high six-figure to low seven-figure reduction in direct labor expense annually from labor efficiency savings.
• Full-year 2025 revenue is projected to be around $64 million, an improvement of approximately $12 million over the prior year.
• Strategic brand partners are expected to outperform the market, with Solsence products typically representing 30-60% of their business volume.
• Operates in the SPF-infused beauty segment, which is expected to be one of the fastest-growing in beauty over the next five years, with consumer preference trending towards mineral-based SPF.
• Holds over 90 globally issued patents across four technology platforms and has won 8 awards for product and technology innovation.
• Management is confident in improving direct margin levels and expects gross margins to normalize back to 30%+ levels within the next couple of quarters, with a long-term objective of 40%+.
• Received a $1.2 million Employee Retention Credit (ERC) payment and $300,000 in related interest in Q2 2025.

Negatives

• Q3 2025 revenue decreased 14% year-over-year to $14.5 million from $16.9 million.
• Gross margin significantly declined to 23% from 36% in Q3 2024.
• Gross profit decreased to $3.4 million from $6.1 million in Q3 2024.
• Reported a net loss of $1.1 million in Q3 2025, compared to net income of $3.0 million in Q3 2024.
• Adjusted EBITDA was a loss of $435,000, compared to a positive $3.6 million in Q3 2024.
• Operating expenses increased to $4.2 million from $2.9 million in Q3 2024, due to increased employee-related costs, legal costs, allowance for credit loss, severance costs, and Nasdaq uplisting costs.
• Experienced a challenging third quarter due to a record Q3 2024 comparable and a general softening in the industry reflecting a shift in consumer behaviors.
• Customers are adjusting inventory levels and providing shorter lead times, impacting revenue.
• Inventory control issues have been a significant challenge due to the increased scope and scale of raw materials (1500+) and products (300+) compared to six years ago.
• Higher indirect expenses during the transition to newer operational structures negatively impacted gross margin.
• Legal fees are currently higher than historical levels.

Risks

• A decision by a customer to cancel a purchase order or supply agreement, given the Company's dependence on a limited number of key customers.
• Uncertain demand for, and acceptance of, the Company's engineered materials, ingredients, and fully formulated products.
• The Company's manufacturing capacity and product mix flexibility in light of customer demand.
• The Company's limited marketing experience.
• Changes in development and distribution relationships.
• The impact of competitive products and technologies.
• The Company's dependence on patents and protection of proprietary information.
• The resolution of litigation in which the Company may become involved.
• The impact of any potential new government regulations that could be difficult to respond to or too costly to comply with while remaining financially viable.
• The ability of the Company to maintain an appropriate electronic trading venue.
• General industry and market conditions and growth rates.
• Possible disruption in commercial activities occasioned by public health issues, terrorist activity, and armed conflict.

Future Outlook

Management expects full-year 2025 revenue to be around $64 million, an improvement of approximately $12 million over the prior year. The company is confident in improving direct margin levels and expects gross margins to normalize back to levels seen a year ago (around 30-36%) over the next couple of quarters. While the overall consumer market and beauty industry are slowing, Solsence anticipates its growth rate will remain a multiple of the industry's growth rate, particularly in the SPF-infused beauty and mineral-based SPF segments. The long-term objective is to achieve gross margins in the 40-plus-percent range. An investor presentation will be released in the coming weeks to provide further guidance for 2026 and beyond.

Management Comments

• "At the same time, we are dedicated to expanding the reach of our skin care, sun care and color cosmetic solutions to consumers who are passionate for our products. Despite a challenging third quarter, we are confident that our wider organizational and commercial strategies will solidify Solsence's future as a dynamic, highly profitable growth company." Kevin Cureton, President and CEO.
• "Our recent structural changes focused on streamlining operations, enhancing product integrity, and improving productivity have strategically positioned Solsence for scaled growth." Laura Riffner, CFO.
• "We reorganized vital parts of the business—specifically unifying our R&D and Quality teams, consolidating manufacturing, and increasing production automation. The culmination of all these efforts will provide the sound operational foundation necessary to efficiently deliver the highest quality products to our brand partners, solidifying our position with them as their long-term partner of choice." Laura Riffner, CFO.
• "The third quarter of 2025 represented the first quarter in almost two years where we did not have a year-over-year revenue increase. Admittedly, Q3 2024 was a record quarter for our company in both revenue and profitability, and represented the level of profitability and performance we expect so the comparison was going to be difficult. However, we remain confident in our ability, both on a near-term and a long-term basis, to continue growing at a multiple of the industry's growth rate and to remain highly profitable while doing so." Kevin Cureton, President and CEO.
• "Our expectation on a full-year basis is that we will see an improvement over prior year. So yes, I think that in total, you'll see a positive revenue versus 2024." Kevin Cureton, President and CEO.
• "Our goal is 30% is really the floor for our guidance, not the ceiling. And so just -that's all we're going to be prepared to say today, at least on 2026. In terms of COVID era margins... we expect to achieve margins in that 40-plus-percent range. That is an objective for our business." Kevin Cureton, President and CEO.
• "We also accept the criticism that the company needs to improve in operations. And that's really a reflection of a lot of the changes that we've made and announced." Kevin Cureton, President and CEO.
• "The future of Sun Care is the future of beauty." Kevin Cureton, President and CEO.

Industry Context

Solsence operates in the beauty and life science categories, specifically focusing on scientifically-driven health care solutions, including skin care, sun care, and color cosmetics, with a strong emphasis on mineral-based SPF technology. The company notes a general softening in the industry and a shift in consumer behaviors, leading to customers adjusting inventory levels and providing shorter lead times. However, the SPF-infused beauty segment, where Solsence specializes, is expected to be one of the fastest-growing segments over the next five years. Consumer preference is also trending towards mineral-based SPF, which benefits Solsence due to its technological leadership and patented solutions in this area, enabling preferential aesthetics like transparency and lightness.

Comparison to Industry Standards

• Solsence has grown at a Compound Annual Growth Rate (CAGR) of greater than 7X compared to its addressable market in skin care, color cosmetics, and sun care cosmetic areas.
• The company has won 8 awards for product and technology innovation, demonstrating industry recognition.
• Management states that the complexity and difficult logistics involved in creating their products create substantial barriers to entry, limiting the number of potential competitors.
• Possesses a unique mix of expertise, best-in-class technology, and manufacturing capabilities that few can match in the industry.
• Solsence products are important drivers for strategic brand partners' revenue, typically representing 30-60% of their business volume, indicating strong market integration.
• Brand partners are successfully competing in key retail segments such as specialty beauty retailers, TikTok, and Amazon.
• The company aims to achieve gross margins in the 40-plus-percent range, viewing itself as a technology leader, which would be a strong performance compared to many manufacturing-heavy industries.

Management Changes

Corporate Governance

Legal Proceedings

• A past BASF lawsuit was mentioned, which was settled amicably, described as 'commercial points of difference' rather than a contractual mistake. No new legal proceedings were detailed.
• The resolution of litigation in which the Company may become involved is listed as a forward-looking risk.

Related Party Transactions

• Line of credit, accounts receivable, related party: $5,316,000 as of September 30, 2025.
• Current portion of line of credit, inventory, related party: $4,000,000 as of December 31, 2024.
• Long-term portion of line of credit, inventory, related party: $9,500,000 as of September 30, 2025.
• Current portion of debt, related parties: $1,000,000 as of December 31, 2024.
• Long-term portion of debt, related parties: $1,000,000 as of September 30, 2025.

Stakeholder Impact

• Shareholders: Negative impact from Q3 net loss and reduced gross margin; potential positive impact from strategic transformation, expected future profitability improvements, and long-term growth in a favorable market segment.
• Employees: Changes in leadership roles (promotions, new hires), reorganization of R&D/Quality teams, and operational restructuring (facility consolidation, labor efficiency improvements) will affect employees. Severance costs were incurred.
• Customers (Brand Partners): Company aims to deliver highest quality products more efficiently, solidifying its position as a long-term partner of choice. Customers are adjusting inventory levels and providing shorter lead times, impacting Solsence's revenue.
• Suppliers: Increased material surveillance and control, and changes in supply chain management, could impact supplier relationships and requirements.
• Creditors: Related party lines of credit and debt are significant on the balance sheet.

Next Steps

• Continue strategic transformation to drive future innovation and growth.
• Improve overall indirect costs over the next couple of quarters to normalize gross margins.
• Release the first investor presentation in the coming weeks to provide further guidance for 2026 and beyond.
• Continue efforts to improve product design, labor efficiency, and inventory control through increased material surveillance and corrective actions.

Key Dates

Recommendation

While Q3 2025 financial results were poor, the company is undergoing a significant strategic overhaul with new leadership and operational improvements aimed at addressing past inefficiencies. The long-term market trends for mineral-based SPF beauty products are favorable, and management has articulated a clear path to improved profitability and growth. However, the immediate financial performance and the time required for the strategic changes to fully materialize warrant a cautious 'Hold' rather than a 'Buy' until clearer signs of sustained financial recovery are evident. The company's confidence in achieving 30%+ gross margins and targeting 40%+ in the long term, combined with its technological leadership, provides a basis for holding, but the execution risk remains.

Keywords

Solsence, SLSN, financial results, Q3 2025, earnings, revenue, net loss, gross margin, EBITDA, executive leadership, operational efficiency, manufacturing consolidation, product development, innovation, beauty, life science, skin care, sun care, color cosmetics, mineral-based SPF, corporate governance, SEC filing, 8-K